Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Upstream Bio, Inc.

UPB · Nasdaq · CIK 0002022626 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

10 Form 4 transaction lines observed in the same window
10 sales · 0 option, withholding, award, gift or other lines

Last qualifying purchase2024-10-15 · Chimovits Erez · $14.0M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
GRAY MICHAELCFO and COO
▼▼
Sutherland Everett RandChief Executive Officer
▼▼
Houghton AdamChief Business Officer
▼▼
Deykin AaronChief Medical Officer
▼▼
Ambrose AllisonGeneral Counsel
▼▼
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-10-15 · Chimovits Erez.

Recent Form 4 activity

0Purchases
15Sales
5Other Form 4 lines
20SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING10 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
4,514,865
Previous report
4,490,724
Avg daily volume
587,966
Days to cover
7.7

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2024-10-15ORBIMED ADVISORS LLC; OrbiMed Advisors Israel II Ltd; OrbiMed Capital GP VIII LLC; OrbiMed Israel GP II, L.P.Purchase (P)Common Stock825,000USD 17.00USD 14,025,000SEC filing ↗
2024-10-15Chimovits ErezPurchase (P)Common Stock825,000USD 17.00USD 14,025,000SEC filing ↗
2024-10-15ACCESS INDUSTRIES MANAGEMENT, LLC; AI Biotechnology LLC; AI Upstream LLC; Access Industries Holdings LLC; Blavatnik LenPurchase (P)Common Stock1,175,000USD 17.00USD 19,975,000SEC filing ↗

Form 4 evidence

20 transaction lines in the latest 365-day window; 32 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-16Sutherland Everett RandSale (S)Common Stock2,095USD 5.49USD 11,502SEC filing ↗
2026-09-16Houghton AdamSale (S)Common Stock700USD 5.49USD 3,843SEC filing ↗
2026-09-16GRAY MICHAELSale (S)Common Stock853USD 5.49USD 4,683SEC filing ↗
Show recent Form 4 evidence (20 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-16Sutherland Everett RandSale (S)Common Stock2,095USD 5.49USD 11,502SEC filing ↗
2026-09-16Houghton AdamSale (S)Common Stock700USD 5.49USD 3,843SEC filing ↗
2026-09-16GRAY MICHAELSale (S)Common Stock853USD 5.49USD 4,683SEC filing ↗
2026-09-16Deykin AaronSale (S)Common Stock895USD 5.49USD 4,914SEC filing ↗
2026-09-16Ambrose AllisonSale (S)Common Stock485USD 5.49USD 2,663SEC filing ↗
2026-06-16Sutherland Everett RandSale (S)Common Stock2,095USD 6.10USD 12,780SEC filing ↗
2026-06-16Houghton AdamSale (S)Common Stock700USD 6.10USD 4,270SEC filing ↗
2026-06-16GRAY MICHAELSale (S)Common Stock853USD 6.10USD 5,203SEC filing ↗
2026-06-16Deykin AaronSale (S)Common Stock895USD 6.10USD 5,460SEC filing ↗
2026-06-16Ambrose AllisonSale (S)Common Stock477USD 6.10USD 2,910SEC filing ↗
2026-03-16Sutherland Everett RandSale (S)Common Stock2,093USD 9.29USD 19,444SEC filing ↗
2026-03-16Houghton AdamSale (S)Common Stock699USD 9.29USD 6,494SEC filing ↗
2026-03-16GRAY MICHAELSale (S)Common Stock852USD 9.29USD 7,915SEC filing ↗
2026-03-16Deykin AaronSale (S)Common Stock894USD 9.29USD 8,305SEC filing ↗
2026-03-16Ambrose AllisonSale (S)Common Stock475USD 9.29USD 4,413SEC filing ↗
2026-01-02Sutherland Everett RandAward / grant (A)Common Stock75,000USD 0.00USD 0SEC filing ↗
2026-01-02Houghton AdamAward / grant (A)Common Stock25,000USD 0.00USD 0SEC filing ↗
2026-01-02GRAY MICHAELAward / grant (A)Common Stock30,500USD 0.00USD 0SEC filing ↗
2026-01-02Deykin AaronAward / grant (A)Common Stock32,000USD 0.00USD 0SEC filing ↗
2026-01-02Ambrose AllisonAward / grant (A)Common Stock17,000USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerUPB
CIK0002022626
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history32 transaction lines from 2024-10-15 to 2026-09-16
5 P purchase lines · 15 S sale lines · 12 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.